TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER

Background

- In 2011, an estimate of 435,000 cases with CDI was reported and 29,000 deaths occurred as the result of the disease.
- The financial burden of U.S. health care relating to CDI was immense, costing about \$4.8 billion.
- Probiotic has been a major debate in literature whether it should be recommended for primary prevention of CDI.
- The strain that was found to have the most prominent data in reducing CDI rate is *Lactobacillus casei* according to a meta-analysis.
- Lactobacillus acidophilus, Lactobacillus casei, and Lactobacillus rhamnosus have been used in conjunction to standard protective measures at a community hospital in the Quebec region to reduce the incidence of CDI.

Purpose

• To determine if a pharmacist-driven protocol using combination strains of Lactobacillus acidophilus, Lactobacillus casei, and Lactobacillus rhamnosus would help to reduce the incidence of CDI

Methods

Study design


- Single-center, observational, retrospective cohort pre-post study
- Data collection period
- Pre-implementation data: October to February 2017
- Post-implementation data: October to February 2018
- Inclusion criteria
- Hospitalist's patient
- Patients who received probiotics within 48 hours of administration of the following antibiotics: Piperacillin/ tazobactam, ampicillin/sulbactam, ceftriaxone, levofloxacin, cefepime, ciprofloxacin, meropenem, imipenem, clindamycin, and ceftazidime

Pharmacist-driven protocol approved by Pharmacy & Therapeutics and Performance Improvement committee was implemented to automatically start probiotic if patient meets criteria and has no exclusion

Effect of a pharmacist-driven management protocol on the probiotic combination of Lactobacillus strains for prevention of Clostridium difficile infection (CDI) in hospitalized adult patients

Uyen Huynh, Pharm.D.^{1.2}, Gregory K. Perry, Pharm.D., BCPS-AQID, BCIDP², Young R. Lee, Pharm.D., BCPS, BCCCP¹, Pete Palmere, Pharm.D. Candidate^{1.2}

¹Texas Tech University Health Sciences Center School of Pharmacy, Abilene, Texas, ²Hendrick Medical Center, Abilene, Texas



	Pre- implementation (n = 218)	Post- implementation (n = 239)
	60.0	61.7
	85.7	88.2
	5.1	5.4
	23.9	28.9
	30.7	25.5
	40.0	40.2
	50.9	56.9
	49.1	43.1
	6	8
	10	9
lays (%)	28.0	28.9
	6.9	5.51
	2.3	5.9
	3.7	0.8
	0.9	1.3
	22.5	8.4
	21.6	22.6
	30.7	45.6
	23.9	23.0
on (%)	64.7	49.4
	53.7	47.7
	79.4	63.2

1º & 2º Outco

Primary outcomes Incidence of CDI d

- Mild to modera
- Severe (n, %)
- Severe, complic

Secondary outcon

- Antibiotic-assoc hospitalization
- Hospital length

Safety

Lactobacillus ba

probiotic.

- also shorter.

this finding.

- patients.

- S144–S147.



Table 2. Outcomes				
comes and Safety results	Pre- implementation (n = 218)	Post- implementation (n = 239)		
es during hospitalization (n, %) ate (n, %)	6 (2.75) 3 (1.38) 2 (0.92)	6 (2.51) 2 (0.84) 4 (1.67)		
icated (n, %) mes	1 (0.46)	0 (0.0)		
ociated diarrhea (AAD) during (n, %)	36 (15.5)	22 (9.21)		
n of stay (mean in days)	8.52	6.62		
acteremia (n, %)	0 (0.0)	0 (0.0)		

Discussion

• Since the p-value for primary outcome is 0.884, there is no significant reduction in the rate of CDI using *Lactobacillus* strains

• For secondary outcomes, AAD rate is significantly less in the probiotic group as p-value = 0.021 and hospital length of stay is

Limitations include single center and retrospective study, extensive exclusion criteria, inclusion of only hospitalist's patients, and potential confounding factors.

Conclusion

• The study with larger sample size is warranted in order to confirm

• Combination of *Lactobacillus* strains probiotic has the potential to reduce AAD and hospital length of stay in hospitalized adult

Disclosure

• The authors of this study do not have any conflicts of interest.

References

1) Lessa et al. The New England Journal of Medicine. 2015, 372;9; 825-34. 2) Cai et al. *UEG Journal* 2018, 6(2), 169-180. 3) Maziade, P.; Pereira, P.; Goldstein, E. Clin. Infect. Dis. 2015, 60 (Suppl. 2),

